Investor Information
Latest News
-
Company Believes U.S. Justice Department Is Fundamentally Wrong, Will Contest Charges Vigorously
April 9, 2019 | PDF Version
-
Indivior Announces New Study Data in Patients with Moderate to Severe Opioid Use Disorder (OUD) at the 50th ASAM Annual Conference
April 8, 2019 | PDF Version
-
Indivior’s RECOVER™ Study Finds Three-quarters of Patients with Moderate to Severe Opioid Use Disorder Who Received 12 monthly Injections of SUBLOCADE™ (Buprenorphine Extended-Release) Injection were Abstinent from Illicit Opioids One Year Later
April 5, 2019 | PDF Version
-
Annual Report & Accounts 2018 and Annual General Meeting 2019
March 14, 2019 | PDF Version
Our Commitment
Updates on the Department of Justice Action
Get updates and information on Indivior’s ongoing response to the recent action by the U.S. Department of Justice and learn about the company’s unwavering commitment to patients, doctors, and communities fighting opioid addiction.
See more >
Upcoming Events
-
Q1 2019 Results Conference Call
May 2nd -
Q1 2019 Results May 2nd
May 2nd -
FY 2018 Results Presentation on February 14ᵗʰ
Thursday, February 14th -
Stifel 2018 Healthcare Conference
November 13th -
Indivior Announces Upcoming Investor Events
November 6th, 2018 -
Nine Months Year-to-Date & Q3 2018 Results Webcast.
Thursday, November 1st -
Morgan Stanley Conference SUBLOCADE™ Update
September 12th -
Morgan Stanley 16th Annual Global Healthcare Conference
9/13/2018 -
H1 2018 Financial Results Presentation (July 25th)
July 25th -
Webcast Event: Jefferies 2018 Global Healthcare Conference, June 5th at 8:30 a.m. New York City time
June 5th -
2018 Annual General Meeting
May 16th -
Indivior PLC Q1 2018 Financial Results
May 2nd
See more
Webcasts/Audiocasts/Presentations
Click on the headings to view online or download a presentation:
RNS Filings
View Indivior filings with the Regulatory News Service on regulatory and non-regulatory updates.
